

Oligodendrocytes produce amyloid- β and contribute to plaque formation alongside neurons in Alzheimer's disease model mice

Received: 28 September 2023

Accepted: 12 July 2024

Published online: 5 August 2024

 Check for updates

Andrew Octavian Sasmita ^{1,2,14}✉, Constanze Depp ^{1,14}✉, Taisiia Nazarenko^{1,2}, Ting Sun ^{1,3}, Sophie B. Siems¹, Erinne Cherisse Ong ^{1,2}, Yakum B. Nkeh ¹, Carolin Böhler¹, Xuan Yu¹, Bastian Bues ⁴, Lisa Evangelista ⁵, Shuying Mao¹, Barbara Morgado ⁶, Zoe Wu¹, Torben Ruhwedel ^{1,7}, Swati Subramanian¹, Friederike Böresen¹, Katharina Overhoff¹, Lena Spieth¹, Stefan A. Berghoff¹, Katherine Rose Sadleir⁸, Robert Vassar^{8,9}, Simone Eggert¹, Sandra Goebbels¹, Takashi Saito ¹⁰, Takaomi Saido ¹⁰, Gesine Saher ¹, Wiebke Möbius ^{1,7}, Gonçalo Castelo-Branco ³, Hans-Wolfgang Klafki⁶, Oliver Wirths ⁶, Jens Wiltfang ^{6,11}, Sarah Jäkel^{5,12}, Riqiang Yan¹³ & Klaus-Armin Nave ¹✉

Amyloid- β (A β) is thought to be neuronally derived in Alzheimer's disease (AD). However, transcripts of amyloid precursor protein (APP) and amyloidogenic enzymes are equally abundant in oligodendrocytes (OLs). By cell-type-specific deletion of *Bace1* in a humanized knock-in AD model, *APP^{NLGF}*, we demonstrate that OLs and neurons contribute to A β plaque burden. For rapid plaque seeding, excitatory projection neurons must provide a threshold level of A β . Ultimately, our findings are relevant for AD prevention and therapeutic strategies.

In Alzheimer's disease (AD), amyloid- β (A β) production has primarily been attributed to excitatory neurons (ExNs)¹, despite emerging evidence that other cell types might contribute to A β production^{2,3}. Cultured oligodendrocytes (OLs) are capable of generating detectable levels of A β in vitro^{4–6}. Because OL lineage cells are abundantly present in both gray matter and white matter (WM), and myelin alterations have been implicated in AD^{7–9}, we asked whether OLs directly contribute to A β plaque burden in vivo.

We first interrogated multiple sequencing datasets of wild-type (WT) mouse^{9–11} and healthy control human^{12–14} nervous tissue for

expression of amyloidogenic pathway genes (*APP*, *BACE1*, *PSEN1* and *PSEN2*) (Fig. 1 and Extended Data Fig. 1a,b). Depending on the sequencing technology and tissue input, positive cell rates of amyloidogenic transcripts varied, but expression levels were similar between neurons and OLs (Extended Data Fig. 1c,d). We validated the expression of amyloid precursor protein (APP) in murine OLs in vitro and in vivo (Extended Data Fig. 2a,b), alongside human OLs via immunolabeling (Extended Data Fig. 2c). By in situ hybridization (ISH) in human cortical tissue, we found that approximately 50% of all gray matter OLs express considerable levels of *APP* and *BACE1* mRNA in both AD cases

¹Department of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany. ²International Max Planck Research School for Neurosciences, Göttingen, Germany. ³Laboratory of Molecular Neurobiology, Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. ⁴School of Biochemistry and Cell Biology, Biosciences Institute, University College Cork, Cork, Ireland. ⁵Institute for Stroke and Dementia Research, Klinikum Der Universität München, Ludwig-Maximilians-Universität, Munich, Germany. ⁶Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, Göttingen, Germany. ⁷Electron Microscopy Core Unit, Max Planck Institute Multidisciplinary Sciences, Göttingen, Germany. ⁸Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ⁹Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ¹⁰Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Wako, Saitama, Japan. ¹¹German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany. ¹²Munich Cluster for System Neurology (SyNergy), Munich, Germany. ¹³Department of Neuroscience, UConn Health, Farmington, CT, USA. ¹⁴These authors contributed equally: Andrew Octavian Sasmita, Constanze Depp. ✉e-mail: sasmita@mpinat.mpg.de; depp@mpinat.mpg.de; nave@mpinat.mpg.de

and controls (Extended Data Fig. 2d–f). Thus, both mouse and human OLs express the essential components for A β generation.

Next, we created novel AD mouse lines to assess A β contribution from OLs and ExNs separately (Fig. 2a). For this, we employed *APP^{NLGF}* knock-in mice that express a humanized and triple-mutated *APP* in the endogenous *App* locus to circumvent transgenic mouse artifacts. These mice were crossed with *Bace1^{fl/fl}* mice to conditionally knock out *Bace1* (*Bace1* cKO), the rate-limiting enzyme in A β generation, using cell-type-specific *Cre* drivers, namely, *Cnp-Cre* for OLs and *Nex-Cre* for dorsal telencephalic ExNs. We termed the resultant triple-mutant mice *OL-Bace1^{cKO};AD* and *ExN-Bace1^{cKO};AD*, respectively, and compared them to non-*Cre* controls termed *Control;AD*.

We assessed *Cnp-Cre* specificity using a stop-flox tdTomato reporter mouse line as transient neuronal *Cnp-Cre* activity has been detected to varying degrees^{15,16}. In concordance with recent findings¹⁷, only a very low percentage of cortical ($0.756\% \pm 0.057\%$) and hippocampal ($0.468\% \pm 0.111\%$) neurons were tdTomato⁺ (Extended Data Fig. 3). We then validated the cell-type-specific *Bace1* transcript reduction using ISH, whereby *Bace1* transcripts were massively reduced in the intended target cell type (Extended Data Fig. 4). Notably, we confirmed that ExN *Bace1* transcript levels were unaffected in *OL-Bace1^{cKO};AD* animals (Extended Data Fig. 4a–d, h–m). We next attempted to demonstrate BACE1 protein expression in OLs and to validate successful knockdown in OLs on a protein level in OL cultures from *Control;AD* and *OL-Bace1^{cKO};AD* mice (Extended Data Fig. 5a, b). However, we failed to validate *Bace1* cKO via immunocytochemistry using the 3D5 antibody. We, therefore, investigated the specificity and sensitivity of this antibody in tissue sections by comparing WT animals to constitutive *Bace1* KO animals. We only observed a loss of 3D5 labeling in the mossy fibers in *Bace1* KO (Extended Data Fig. 5c), yet no somatic BACE1 was observed (Extended Data Fig. 5d). As immunohistochemical validation of *Bace1* KO was not feasible, we sorted OLs from *Control;AD* and *OL-Bace1^{cKO};AD* mice and showed abolishment of BACE1 in cKO tissue via immunoblotting by which BACE1 can be readily detected (Extended Data Fig. 5e). We also validated the specificity of the APP antibody Y188 by investigating constitutive APP KO tissue, which revealed loss of both neuronal and OL APP (Extended Data Fig. 5f).

We then turned to western blot analysis to validate APP processing alterations (Extended Data Fig. 5g, h). Full-length APP (FL-APP) levels were 40% lower in control *APP^{NLGF}* lysates compared to WT brains. As expected, both *Bace1* cKOs in ExNs and OLs resulted in a region-dependent depletion of BACE1, reflecting local differences in neuron-to-OL ratio. Of note, WM tracts harbor a substantial amount of axoplasm containing neuronally expressed BACE1 (ref. 18), explaining the reduction seen in the WM of *ExN-Bace1^{cKO};AD* mice. Cell-type-specific losses of BACE1 diminished β C-terminal fragments (β -CTFs) in the cKOs and restored FL-APP to nearly baseline WT amounts. Levels of presenilin-1 (PSEN1) remained unchanged.

Next, we used light sheet microscopy (LSM) for in toto imaging of amyloid plaques in *OL-Bace1^{cKO};AD* and *ExN-Bace1^{cKO};AD* mouse

hemibrains at 6 months in both sexes (Extended Data Fig. 6). We analyzed cortex and hippocampus for gray matter and the alveus as a representative WM tract, alongside the thalamus and inferior colliculus as regions that do not show *Nex-Cre* recombination.

OL-Bace1^{cKO};AD mice accumulated approximately 30% fewer plaques when compared to respective controls in both sexes (Fig. 2b–f). The decrease in plaque amount and plaque size was greatest in the alveus. Microgliosis was proportional to A β plaque pathology (Extended Data Fig. 7). Surprisingly, plaque burden in *ExN-Bace1^{cKO};AD* mice was reduced by 95–98% compared to controls (Fig. 2g–k), which was much more than anticipated given our findings in *OL-Bace1^{cKO};AD*. Accordingly, plaque sizes were smaller, and microgliosis was markedly reduced (Extended Data Fig. 7). Moreover, *ExN-Bace1^{cKO};AD* mice also showed a striking reduction in the amount of thalamic plaques. The unchanged levels of *Bace1* transcript in the thalamus of *ExN-Bace1^{cKO};AD* mice (Extended Data Fig. 8a, b) indicate that a large amount of subcortical A β must be derived from cortico-thalamic axonal projections. Indeed, the inferior colliculus, receiving limited cortical input (Extended Data Fig. 8c) primarily from the auditory cortex¹⁹, was spared from plaque attenuation in *ExN-Bace1^{cKO};AD* mice. In fact, immunolabeling of 5 $\times$ FAD brain slices with the human APP-specific antibody, 1D1, revealed that human APP reactivity in neuronal soma is almost restricted to the cortex (Extended Data Fig. 8d) and hippocampus, confirming the Thy1.2 promoter domain. This further indicates that a subset of dorsal telencephalic neurons is the predominant source of local and distal A β plaques.

It was nonetheless puzzling that plaque burden was reduced by more than 95% in *ExN-Bace1^{cKO};AD* animals, as we had expected that the residual plaque burden would reflect the contribution of OLs (30%). A β fibrillation and plaque formation follow sigmoidal growth kinetics^{20,21}, and a threshold level of A β accumulation is essential for plaque seeding to occur. This threshold level apparently cannot be reached without neuronal A β . Fittingly, compared to homozygous *APP^{NLGF}* mice, heterozygotes did not develop 50% plaque burden but, rather, less than 10% (Extended Data Fig. 8e–g). This highlights the nonlinear relationship among APP processing, A β production and plaque load. Indeed, analysis of 12-month-old *ExN-Bace1^{cKO};AD* mice revealed considerable plaque deposition (Extended Data Fig. 9a, b), hinting that, with enough time, plaques can still be formed by A β from non-ExN sources.


Lastly, we performed a sensitive electrochemiluminescence assay for different A β species (A β 38, A β 40 and A β 42) to determine total A β levels. As inputs, we analyzed soluble and insoluble (representing A β primarily bound in plaques) fractions of microdissected cortex for gray matter and corpus callosum (CC) for WM (Fig. 3a, b). *OL-Bace1^{cKO};AD* brains contained less insoluble and soluble A β 42 compared to controls, especially in the WM. *ExN-Bace1^{cKO};AD* brains were almost devoid of insoluble A β , but a moderate amount ($14.925\% \pm 0.066\%$) of soluble A β 42 was detected in *ExN-Bace1^{cKO};AD* cortical tissue. Additionally, the residual amount of WM A β 42 was higher in *ExN-Bace1^{cKO};AD* brains ($27.604\% \pm 0.072\%$). In short, although plaque amount was marginally

Fig. 1 | OLs abundantly express key amyloidogenic pathway genes as assessed by scRNA-seq and snRNA-seq. **a**, UMAP visualization of cell types from a 6-month-old mouse brain snRNA-seq dataset⁹. **b**, Feature plots showcasing expression of key amyloidogenic genes (*App*, *Bace1*, *Psen1* and *Psen2*) across all cell types in WT mouse brains. **c**, Expression level half violin plots of key amyloidogenic genes in neurons and OLs of mouse brains normalized by the SCTransform method, highlighting the similar expression of all genes between neurons and OLs. **d**, Expression level half violin plots of key amyloidogenic genes in neurons and OLs normalized by the SCTransform normalization method from additional mouse datasets^{9–11}. **e**, Mouse nervous tissue inputs for sequencing from each study are shown. **f**, UMAP visualization of cell types from a human brain snRNA-seq dataset¹². **g**, Feature plots showcasing expression of key amyloidogenic genes (*APP*, *BACE1*, *PSEN1* and *PSEN2*) across all cell types in

control human brains. **h**, Expression level half violin plots of key amyloidogenic genes in neurons and OLs of human brains with the SCTransform normalization method, highlighting the similar expression of these genes between neurons and OLs. **i**, Expression level half violin plots of key amyloidogenic genes in neurons and OLs normalized by the SCTransform normalization method from additional human datasets^{13,14}. **j**, Positive rate bar plots of APP processing genes in mouse and human nervous tissue inputs. **k**, Human nervous tissue inputs for sequencing from each study are shown. **c, d, h, i**, Half violins represent aggregated expression levels of respective genes from each cell type, and data points refer to individual expression levels from single cells or nuclei normalized by SCTransform. The results published here are based on data obtained from the Gene Expression Omnibus and the AD Knowledge Portal. mo, months; UMAP, uniform manifold approximation and projection.

low in the *ExN-Bace1^{cko};AD* brains, an adequate amount of soluble A β was still generated by non-ExN sources of A β , including OLs and potentially other cell types.

To investigate if residual plaques found in *ExN-Bace1^{cko};AD* hemibrains are primarily derived from OLs, we generated *Cnp-Cre Nex-Cre Bace1^{fl/fl} APP^{NLGF}* mice, hereby termed *OL-ExN-Bace1^{cko};AD*.







Fig. 2 | OLs contribute to A β burden primarily derived from ExNs in vivo.

a, Mouse breeding setup to investigate the OL-specific and ExN-specific contributions to A β burden. **b–f**, LSM data of plaque burden (Congo red) comparing 6-month-old *OL-Bace1*^{CKO};AD mice to age-matched and sex-matched littermate controls. **g–k**, LSM data of plaque burden (Congo red) comparing 6-month-old *ExN-Bace1*^{CKO};AD mice to age-matched and sex-matched littermate controls. **b–k**, Color-region allocation is as follows: white, isocortex; blue, hippocampus; yellow, alveus; pastel blue, inferior colliculus; pastel yellow, thalamus. **b, g**, LSM 3D visualization of control and cKO hemibrains. **c, h**, Brain region-segmented plaques of control and cKO hemibrains. **d, i**, LSM 2D single plane of control and cKO hemibrains. Arrowheads point to plaques

with colors indicating specific regions. **e, j**, LSM 3D renders of representative cortical A β plaques of control and cKO hemibrains. **f, k**, Quantification of LSM data between controls ($n = 5$ per sex) and cKOs ($n = 5$ per sex). Normalization of cKO data points to sex-matched controls was performed. Circles represent controls, and triangles represent cKOs. Filled shapes represent male mice, and hollowed shapes represent female mice. For each parameter, unpaired, two-tailed Student's t -test was performed (P values indicated in graphs with significance highlighted in bold) comparing cKOs to controls. Bars represent means with s.e.m., and individual data points are displayed. Raw data are available in Supplementary Tables 1 and 2.



OL-ExN-Bace1^{cko};AD developed almost no plaques in the cerebrum (Extended Data Fig. 9c–e). Moreover, *OL-ExN-Bace1^{cko};AD* lysates showed an almost complete loss of Aβ42 when compared to

ExN-Bace1^{cko};AD samples (Extended Data Fig. 9f), further highlighting that OLs are a main source of Aβ production even in the absence of the ExN contribution.

Fig. 3 | Cell-type-specific deletion of *Bace1* alters the steady-state rate of A β production. **a, b**, A β electrochemiluminescence immunoassay data of insoluble (SDS-soluble, left) and soluble (Tris-NaCl-soluble, right) lysates of microdissected cortical (**a**) and WM (**b**) tissues from control and cKO 6-month-old male mouse hemibrains ($n = 7$ per group). Triplex immunoassay measured A β 38, A β 40 and A β 42 levels, and data points were normalized to *Control*;AD samples. Of note, SDS-soluble fractions from both regions mirrored LSM data, whereas Tris-NaCl-soluble fractions revealed a substantial amount of soluble A β still being produced, even in *ExN-Bace1^{ckO}*;AD mice, signifying a residual

A β production from other cells. Statistical analysis: one-way ANOVA with Tukey multiple comparison tests (P values indicated in graphs with significance highlighted in bold). Bars represent means with s.e.m., and individual data points are displayed. Raw unnormalized data are available in Supplementary Table 6. **c**, Working model of modulating cell-type-specific A β contributions. Selectively ablating A β from specific cell types results in steady-state rate change of A β production, causing exponentially slower plaque growth that follows a sigmoidal growth curve. ctrl, control; rel., relative.

Functionally, cKO of *Bace1* did not result in any changes to neuronal nor axonal abundance (Extended Data Fig. 10a, b). We also recently showed that OL dysfunction drives neuronal amyloid deposition in AD mouse models⁹. To exclude this as a confounding factor, we compared myelin profiles in *OL-Bace1^{ckO}*;AD and *ExN-Bace1^{ckO}*;AD mice but found no changes (Extended Data Fig. 10c–g).

The high expression level of amyloidogenic pathway genes in OLs was contrasted by the smaller relative contribution to overall A β deposition. This could be explained by the differences in number, localization or size between neurons and OLs²². There is also the alternative possibility that A β processing is more efficient in neuronal compartments or that A β isoforms differ between cell types. Beyond their abundance and unique activity profile²³, however, what makes ExNs so efficient at producing A β remains elusive. Identifying the mechanisms that slow down A β generation in OLs, despite the abundance of processing substrate and enzymes, could pave the way for novel therapies targeting A β generation.

In conclusion, we provide, to our knowledge, the first in vivo evidence that OLs, a glial cell type, are key players in AD—even in the context of establishing primary A β pathology. Notably, the 30% plaque reduction in *OL-Bace1^{ckO}*;AD mice falls in the range of effect sizes achieved by aducanumab²⁴ and the FDA-approved lecanemab²⁵ antibody therapies. Potentially, selective targeting of *BACE1* in OLs could spare the detriments of widespread *BACE1* inhibition, especially given the adverse effects seen in *BACE1* inhibitor clinical trials^{26–28}. Additionally, we showed that ExN-derived A β is still required for rapid plaque seeding locally and distally (Fig. 3c). Ultimately, our non-linearity data are relevant when considering anti-A β therapeutic interventions, including *BACE1* inhibitors, which, as suggested^{29,30}, may have potential in preventing amyloidosis before threshold levels are reached.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41593-024-01730-3>.

References

1. Zhao, J. et al. β -secretase processing of the β -amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes. *J. Biol. Chem.* **271**, 31407–31411 (1996).
2. Veeraghavalu, K., Zhang, C., Zhang, X., Tanzi, R. E. & Sisodia, S. S. Age-dependent, non-cell-autonomous deposition of amyloid from synthesis of β -amyloid by cells other than excitatory neurons. *J. Neurosci.* **34**, 3668–3673 (2014).
3. Rice, H. C. et al. Contribution of GABAergic interneurons to amyloid- β plaque pathology in an APP knock-in mouse model. *Mol. Neurodegener.* **15**, 3 (2020).
4. Skaper, S. D., Evans, N. A., Rosin, C., Facci, L. & Richardson, J. C. Oligodendrocytes are a novel source of amyloid peptide generation. *Neurochem. Res.* **34**, 2243–2250 (2009).
5. Walter, S. et al. The metalloprotease ADAMTS4 generates N-truncated A β 4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. *Acta Neuropathol.* **137**, 239–257 (2019).
6. Gazestani, V. et al. Early Alzheimer's disease pathology in human cortex involves transient cell states. *Cell* **186**, 4438–4453.e23 (2023).
7. Chen, J. F. et al. Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer's disease. *Neuron* **109**, 2292–2307 (2021).
8. Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer's disease. *Nature* **570**, 332–337 (2019).
9. Depp, C. et al. Myelin dysfunction drives amyloid- β deposition in models of Alzheimer's disease. *Nature* **618**, 349–357 (2023).
10. Ximerakis, M. et al. Single-cell transcriptomic profiling of the aging mouse brain. *Nat. Neurosci.* **22**, 1696–1708 (2019).
11. Zeisel, A. et al. Molecular architecture of the mouse nervous system. *Cell* **174**, 999–1014 (2018).
12. Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. *Nat. Med.* **26**, 131–142 (2020).
13. Jäkel, S. et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. *Nature* **566**, 543–547 (2019).
14. Lake, B. B. et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. *Nat. Biotechnol.* **36**, 70–80 (2018).
15. Tognatta, R. et al. Transient *Cnp* expression by early progenitors causes Cre-Lox-based reporter lines to map profoundly different fates. *Glia* **65**, 342–359 (2017).
16. Jo, Y. R. et al. Potential neuron-autonomous Purkinje cell degeneration by 2',3'-cyclic nucleotide 3'-phosphodiesterase promoter/Cre-mediated autophagy impairments. *FASEB J.* **35**, e21225 (2021).
17. Lam, M. et al. CNS myelination requires VAMP2/3-mediated membrane expansion in oligodendrocytes. *Nat. Commun.* **13**, 5583 (2022).
18. Hu, X., Hu, J., Dai, L., Trapp, B. & Yan, R. Axonal and Schwann cell *BACE1* is equally required for remyelination of peripheral nerves. *J. Neurosci.* **35**, 3806–3814 (2015).
19. Blackwell, J. M., Lesicko, A. M., Rao, W., De Biasi, M. & Geffen, M. N. Auditory cortex shapes sound responses in the inferior colliculus. *eLife* **9**, e51890 (2020).
20. Lee, C. C., Nayak, A., Sethuraman, A., Belfort, G. & McRae, G. J. A three-stage kinetic model of amyloid fibrillation. *Biophys. J.* **92**, 3448–3458 (2007).
21. Burgold, S., Filser, S., Dorostkar, M. M., Schmidt, B. & Herms, J. In vivo imaging reveals sigmoidal growth kinetic of β -amyloid plaques. *Acta Neuropathol. Commun.* **2**, 30 (2014).
22. Herculano-Houzel, S. The glia/neuron ratio: how it varies uniformly across brain structures and species and what that means for brain physiology and evolution. *Glia* **62**, 1377–1391 (2014).

23. Kamenetz, F. et al. APP processing and synaptic function. *Neuron* **37**, 925–937 (2003).
24. Sevigny, J. et al. The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature* **537**, 50–56 (2016).
25. Tucker, S. et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid- β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. *J. Alzheimers Dis.* **43**, 575–588 (2015).
26. Chatila, Z. K. et al. BACE1 regulates proliferation and neuronal differentiation of newborn cells in the adult hippocampus in mice. *eNeuro* **5**, ENEURO.0067-18.2018 (2018).
27. Sur, C. et al. BACE inhibition causes rapid, regional and non-progressive volume reduction in Alzheimer's disease brain. *Brain* **143**, 3816–3826 (2020).
28. Wessels, A. M. et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. *Alzheimers Dement.* **16**, 1483–1492 (2020).
29. Satir, T. M. et al. Partial reduction of amyloid β production by β -secretase inhibitors does not decrease synaptic transmission. *Alzheimers Res. Ther.* **12**, 63 (2020).
30. Peters, F. et al. BACE1 inhibition more effectively suppresses initiation than progression of β -amyloid pathology. *Acta Neuropathol.* **135**, 695–710 (2018).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

Methods

Reanalysis of single-nucleus RNA sequencing and single-cell RNA sequencing data from mouse and human nervous system

Single-cell/single-nucleus RNA sequencing (snRNA-seq/scRNA-seq) datasets were collected and screened for expressions of *APP*, *BACE1*, *PSEN1* and *PSEN2* across major cell populations in the central nervous system (CNS). In total, four mouse datasets^{9–11} and three human datasets^{12–14} were used. The in-house generated data underwent alignment toward reference genome GRCm38/mm10 using the Cell Ranger toolkit (10x Genomics), where other external datasets were processed from raw count matrices. All data were processed with the R package Seurat (version 4.3.0)³¹ based on original study protocols. Cell type annotations were cross-checked with cluster-specific gene signatures. Afterward, major CNS cell populations, including excitatory neuron (Ext_Neuron), inhibitory neuron (Inh_Neuron), oligodendrocyte precursor cell (OPC), newly formed oligodendrocyte (NFOL), mature oligodendrocyte (MOL), astrocyte (AST), microglia (MG), endothelial cells (Endo) and pericyte, were subset for further screening for APP metabolism-related gene expressions. Each subset dataset underwent renormalization, high variable feature calculation and scaling using the SCTransform pipeline with default parameters. Gene expression levels are visualized in half violin plots using the R package raincloudplots (version 0.0.4)³². The positive expression rate of each gene was calculated upon more than one unique molecular identifier (UMI), and the relative proportion is visualized using the R package ggplot2 (version 3.4.4)³³.

Mouse models, husbandry and genotyping

All animal experiments were conducted in concordance with German animal welfare practices and local authorities (documentation: 24_KAN_0021_CNCBFL, 24_KAN_0026_NXCBFL and 24_KAN_0024_FFDE). Mice were group-housed in the animal facility of the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT), City Campus, with ad libitum food and regular cage maintenance. All mice were kept under a 12-h dark and 12-h light cycle in an ambient temperature of 21 °C and 45% humidity. All animals are characterized as unburdened, and only organ collection was performed. Mouse strains were kept on a C57BL/6N background. Both sexes were used and indicated in the respective figures. The following mouse strains were used: *APP*^{NLGF} (ref. 34), *Bace1*^{fl/fl} (ref. 35), *Cnp*^{Cre/+} hereby termed *Cnp-Cre*³⁶, *Nex-Cre*³⁷, stop-flox tdTomato³⁸ and 5×FAD³⁹. The crossbreeds generated and analyzed are as follows: *Cnp-Cre Bace1*^{fl/fl} *APP*^{NLGF} to assess OL-Aβ contribution (*OL-Bace1*^{CKO};AD); *Nex-Cre Bace1*^{fl/fl} *APP*^{NLGF} (*ExN-Bace1*^{CKO};AD) to assess ExN-Aβ contribution; and *Cnp-Cre* stop-flox tdTomato to validate *Cnp-Cre* specificity. *Bace1*^{−/−} samples were provided by the laboratory of Robert J. Vassar. *App*^{−/−} samples were provided by the laboratory of Ulrike Müller. Ages of animals analyzed are listed on the respective figures. Genotyping was carried out on ear clips from the marking process (see individual strain references for genotyping protocols). Re-genotyping was performed on a small tail biopsy gathered after mice were euthanized. Most experimental cohorts were defined by genotype, and littermate controls were analyzed.

Mouse tissue extraction

To acquire samples for imaging experiments, animals were euthanized and immediately flushed with cold PBS until the liver was decolorized. Extracted tissues underwent overnight immersive fixation in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer before switching to PBS for long-term storage at 4 °C. For electron microscopy, perfusion was done with 4% PFA and 2.5% glutaraldehyde in 0.1 M phosphate buffer (K+S buffer) after flushing with PBS and stored at 4 °C long term in 1% PFA in PBS. For biochemical experiments, animals were cervically dislocated, and their brains were quickly extracted before a quick wash in PBS. Tissues were then placed into a custom 1-mm-spaced coronal brain matrix developed in-house (Workshop, MPI-NAT, City Campus) for manual, sequential sectioning with blades. Brain slices were

transferred to a glass plate on ice before microdissection of cortices, CC and hippocampi. Dissected tissues were snap frozen and placed in −80 °C until further use.

Sample preparation and staining for LSM

Fixed tissues were processed for LSM imaging using a modified iDISCO protocol optimized for amyloid plaque staining, as previously reported⁹. Hemibrains were subjected to a sequence of dehydration, autofluorescence quenching, permeabilization and labeling with Congo red dye. After labeling, hemibrains were subjected to a final ascending methanol wash in PBS and overnight incubation in a 1:2 mixture of 100% methanol and dichloromethane (DCM). Finally, the samples were placed in 100% DCM for 1 h 40 min before clearing in ethyl cinnamate (ECI) for imaging.

In toto LSM imaging and analysis

Cleared hemibrains were imaged with an LSM setup (UltraMicroscope II, LaVision Biotec) with a corrected dipping cap at ×2 objective lens magnification. InspectorPro (version 7.124, LaVision Biotec) software was used to visualize the samples in the mosaic acquisition mode with the following settings: 5-μm light sheet thickness, 20% sheet width, 0.154 sheet numerical aperture, 4-μm z-step size, 2,150 × 2,150 pixels field of view, dynamic focus steps of 5, dual light sheet illumination and 100-ms camera exposure time. Red fluorescence of Congo red-stained hemibrains was recorded with 561-nm laser excitation at 80% laser power and a 585/40-nm emission filter. Image stacks were imported and stitched with Vision4D (version 3.2, Arivis). Regions of interest (ROIs) in this study include isocortex, hippocampus, alveus, inferior colliculus and thalamus. The ROIs were defined based on anatomical landmarks and labeled before segmentation of plaque burden. A machine learning pipeline to extrapolate three-dimensional (3D) shape recognition from two-dimensional (2D) inputs was generated by supplementing 200 desired objects (plaques) and backgrounds (non-plaque structures), respectively. Next, segment co-localization was performed to delineate plaques within specific ROIs. Upon acquiring plaques as voxel objects, noise was removed by deleting objects with voxel sizes 1–10 and plane counts 1–3. Lastly, object metadata and correlated features were exported as spreadsheets.

Paraffin sample preparation and immunohistochemical staining

Preparation of paraffinized samples and immunohistochemistry (IHC) were performed as previously described⁹. Details of antibodies used for IHC are listed in Supplementary Tables 7 and 8. Nuclei were stained with DAPI (Thermo Fisher Scientific, 300 nM) in PBS. Slides were washed in PBS twice for 5 min and mounted with Aqua-Poly/Mount medium (Polysciences). Finally, slides were left to dry overnight before imaging.

Vibratome sectioning and immunostaining

Fixed hemibrains were sectioned at 30-μm thickness with a VT 1000S microtome (Leica). Selected vibratome sections were placed into a 12-well plate with 1 ml of TBS in each well. The sections were rinsed three times in PBS for 5 min. For 3D5 immunolabeling, the sections were placed in a 0.1 M sodium citrate pH 9.0 buffer for antigen retrieval. Sections were then incubated in 16 mM glycine in TBS-0.1% Triton solution for 1 h, followed by washing with TBS three times for 5 min each. Blocking was performed in 5% donkey serum in TBS with 0.1% Triton X-100 for 1 h with shaking. Sections were washed twice for 10 min in 1% BSA in TBS with 0.1% Triton X-100 with shaking. Next, the designated primary antibodies (500 μl per well) were applied onto the sections in 1% BSA in TBS-0.1% Triton overnight at 4 °C with shaking. The following primary antibodies were used: anti-BACE1-3D5 (mouse, hybridoma culture supernatant, 1:250) and anti-BACE1-ab183612 (rabbit, Abcam, 1:250). The next day, sections were washed three times for 10 min each in 1% BSA/0.21% Triton-TBS with shaking. Fluorescent secondary antibodies (500 μl per well) were applied in 1% BSA in TBS-0.25% Triton for 2 h

in the dark. The following secondary antibodies were used: anti-rabbit Alexa Fluor 555 (donkey/goat, Thermo Fisher Scientific, 1:1,000) and anti-mouse Alexa Fluor 555 (donkey/goat, Thermo Fisher Scientific, 1:1,000). Nuclei were stained with DAPI (Thermo Fisher Scientific, 300 nM) in PBS. Finally, the sections were washed three times for 15 min each in TBS in the dark with shaking. Sections were carefully retrieved from the 12-well plate and mounted with Aqua-Poly/Mount medium (Polysciences). Slides were left to dry overnight before imaging.

Human tissue collection

Human patient samples (control—one female, two male, age: 74 ± 2.83 years; AD—two female, two male, age: 72.75 ± 1.78 years) were obtained from Neurobiobank Munich with ethical approval from the Ethical Committee at Ludwig-Maximilians University. Selection of patients was performed upon Braak staging with scores of patients with AD ranging from Braak 5 to 6 and control patient scores ranging from Braak 1 to 3. Postmortem interval of patients ranged between 26 h and 51 h. APOE genotype of all control patients is 3/3, and APOE genotypes of patients with AD are 3/3, 3/4 and 4/4. For ISH experiments, formalin-fixed paraffin-embedded tissue sections were used from human samples.

ISH

We employed the RNAscope Fluorescent Multiplex assay (ACDBio) for paraffin-embedded samples (5- μ m mouse and 4- μ m human sections) as previously described⁹. To ensure optimal hybridization, a hydrophobic barrier was created followed by protein digestion via incubation in RNAscope Protease Plus at 40 °C for 15 min (mouse) or RNAscope Protease IV for 20 min (human). The following probes were used: Mm-Mbp (451491-C1), Mm-Bace1-C2 (400721-C2), Mm-Slc17a7-C3 (416631-C3), Hs-MBP-C2 (411051-C2), Hs-APP-C1 (418321-C1) or Hs-BACE1-C3 (422541-C3) at 40 °C for 2 h. For triple visualization of mouse sections, the following fluorophores were applied: Opal 520, 570 and 690, at 40 °C for 30 min. For double visualization of human sections, TSA Vivid Fluorophores (570 and 650) were used. The slides were again washed and stained with DAPI (Thermo Fisher Scientific, 300 nM) for 10 min before mounting with Aqua-Poly/Mount medium (Polysciences).

Upon epifluorescence imaging, validation of *Bace1* deletion in mouse cortical ExNs was performed manually due to the presence of ample satellite OLs in the cortex. A 500- μ m-wide ROI spanning all cortical layers was drawn for each coronal brain slice, more specifically in the parietal or somatosensory cortex overlying the hippocampus. For nuclei expressing *Slc17a7*, *Bace1* puncta were quantified to yield individual ExN *Bace1* counts. The data were grouped into distinct cortical layers, which were delineated based on landmarks. Similar manual quantification was also performed on *Mbp*⁺ OLs in the fimbria. Validation of *Bace1* deletion in hippocampal ExNs was carried out semi-automatically by creating a pipeline employing a nuclear detection plugin (StarDist) and expanding the captured nuclear ROIs by a pixel size of 10. Combined with particle analyzer and watershed binarization, *Bace1* puncta were detected per hippocampal neuron. For human samples, images of the entire human brain sections were acquired with the PANNORAMIC Midi II Slide Scanner (3DHISTECH) with the $\times 20$ objective and smaller selected regions with the $\times 40$ objective. The human cortex was divided into three areas corresponding to layers 1 and 2 (L1–2), layers 3 and 4 (L3–4) and layers 5 and 6 (L5–6). For each area, 6–12 images of similar size were selected using CaseViewer (version 2.4, 3DHISTECH) and exported via Slide Converter (version 2.3.2, 3DHISTECH). Selected images were randomized using a Fiji filename-randomizer plugin, and counting was done using the Fiji CellCounter plugin.

In vitro OL culture

OPCs were isolated from p7 mouse brains using magnetic-activated cell sorting (MACS) and anti-NG2 MicroBeads (Miltenyi Biotec). Tissue dissection and cell sorting were performed under sterile conditions.

The neural tissue dissociation kit was used according to the manufacturer's protocol and as described⁴⁰. Dissected brains were transferred into enzyme mix 1, followed by incubation at 37 °C for 15 min. Next, incubation with enzyme mix 2 was done at 37 °C for 20 min with manual dissociation. Tubes were centrifuged at 1,200 r.p.m. for 5 min, and the supernatant was decanted while the pellet was resuspended in DMEM with 1% horse serum. We then passed the cell suspension through a 70- μ m and then a 40- μ m strainer. The tubes were again centrifuged at 1,200 r.p.m. for 10 min, and the pellet was resuspended and incubated in warm OPC culture medium consisting of 100 ml of NeuroMACS media, 2 ml of MACS NeuroBrew21, 1 ml of penicillin–streptomycin and 1 ml of L-Glutamax at 37 °C for 2 h. Next, tubes were centrifuged at 1,200 r.p.m. and 4 °C for 10 min, followed by pellet resuspension and incubation in NG2 MicroBeads diluted in DMEM with 1% horse serum (10 μ l of NG2 beads per 10^7 total cells) at 4 °C for 15 min. The cell suspension was again centrifuged at 1,200 r.p.m. and 4 °C for 10 min, and the supernatant was removed before pellet resuspension in 5 ml of DMEM with 1% horse serum. LS columns (Miltenyi Biotec) were first attached to a magnet before activating with DMEM containing 1% horse serum. The columns were washed three times with DMEM after addition of the cell suspension. The columns were finally detached from the magnet and flushed with 5 ml of DMEM containing 1% horse serum to collect bound cells. Upon detachment, samples were centrifuged at 1,200 r.p.m. for 5 min, and the pellet was resuspended in proliferation medium. OPCs were plated at a density of 1.2×10^5 cells per well on a 12-well plate in proliferation medium, before replacement with OPC differentiation medium at 4 days in vitro (DIV4). Cells were fixed at DIV8 with 4% PFA and washed with PBS three times for 5 min each.

Immunocytochemical staining

For immunocytochemical labeling, cells were permeabilized with cold 0.3% Triton X-100 in PBS and blocked with 10% goat serum and 0.03% Triton X-100 in PBS for 1 h. Primary antibodies were diluted in 1.5% horse serum in PBS and applied at 4 °C overnight. Coverslips were washed with PBS three times for 5 min and incubated in secondary antibodies diluted in PBS for 1 h. Details of antibodies used for immunocytochemistry are listed in Supplementary Tables 7 and 8. The samples were washed twice for 5 min before incubation with DAPI (Thermo Fisher Scientific, 300 nM) in PBS. Lastly, cells were washed briefly in PBS before mounting with Aqua-Poly/Mount for confocal imaging. All incubation steps were done at room temperature unless stated otherwise.

Epifluorescence and confocal microscopy

Epifluorescence imaging was carried out with parameters as previously described⁴. Resulting tiled images were stitched in ZEN. For confocal microscopy, images were partially acquired via ZEN software with a Zeiss LSM 800 Airyscan confocal microscope equipped with Plan-Apochromat $\times 63/1.4$ oil DIC M27 objective. Alternatively, images were acquired via LasAF software with a Leica SP8 Lightning confocal microscope equipped with an argon laser and a tuneable white-light laser with $\times 63/1.4$ glycerin objective. Both confocal microscopes are situated at the European Neuroscience Institute and at MPI-NAT, City Campus, respectively.

Analysis of 2D microscopy images

All 2D image analysis was performed on Fiji (version 1.53c)⁴¹. For validation of *Cnp-Cre* specificity, thresholding and particle analyzer were performed to segment and quantify neurons, OLs and RFP⁺ cells. Quantification of RFP⁺ OLs in the CC, however, was performed manually due to the dense amount of OLs. Quantification of 2D A β and microgliosis was done via thresholding and measurement of positive area. Microscopic analysis of OL numbers between controls and cKOs similarly started with ROI segmentation followed by thresholding and particle analyzer. As for OL numbers in WM tracts, manual quantification was again performed.

Finally, percentage ROI area of the cortex and hippocampus occupied by myelinated structures was obtained upon thresholding, and mean intensity values of major WM tracts were measured.

Electron microscopy

Sample preparation for electron microscopy was performed based on an optimized protocol in the working group⁹. At least ten digital pictures were captured at $\times 4,000$ magnification with a Zeiss EM900 for ultrastructural analysis. Electron micrographs of the caudal CC were analyzed with Fiji. Analysis of g-ratio was conducted as previously described⁹.

MACS of OLs

OLs were isolated from whole brains (excluding the olfactory bulb and the cerebellum) of 1-month-old mice using an adult brain dissociation kit (Miltenyi Biotec, 130-107-677). OLs were sorted via positive selection by labeling with OL-specific anti-O4 MicroBeads (Miltenyi Biotec, 130-096-670, 1:40). Sorted cells were eluted in $1\times$ PBS containing cOmplete Mini protease inhibitor cocktail (Roche, one tablet per 10 ml of $1\times$ PBS) and PhosSTOP (Roche, one tablet per 10 ml of $1\times$ PBS) and were centrifuged at 13,000 r.p.m. for 5 min. Pellets were snap frozen for further protein analysis and stored at -80°C . For western blotting, the pellets were resuspended in 28.5 μl of RIPA buffer taken from an aliquot of 10 ml containing one tablet of protease inhibitor and one tablet of phosphatase inhibitor. This was followed by sonication for 3 min in an ultrasonic bath. For loading, 30 μl of $2\times$ Tris-tricine sample buffer (Invitrogen) was added, as was 1.5 μl of 2 MDTT.

Protein fractionation

Preparation of insoluble and soluble fractions from mouse brain tissue was carried out based on a modified protocol⁴². Tissue homogenization was carried out using a homogenizer (Precellys) on microdissected cortical and CC fractions in reaction tubes containing ceramic beads in cold lysis buffer (pH 8.0) (700 μl for cortex and 500 μl for CC). The following settings were used for the homogenization at 4°C : 6,500g twice for 30 s. The homogenate was carefully transferred to a 1.5-ml reaction tube before spinning with a benchtop centrifuge (Eppendorf) at 17,000g and 4°C for 20 min. The supernatant was collected and served as the soluble protein fraction, while the pellet was resuspended in 2% SDS (500 μl for cortex and 300 μl for CC). The solution was then sonicated on ice for 1 min until the pellet completely dissolved. To remove DNA, 1 μl of benzonase was added into the solution and incubated at room temperature for 5 min. The samples were again centrifuged at 17,000g and 4°C for 20 min before transferring the supernatant to a fresh collection tube, serving as the insoluble fraction. Fractions were stored at -80°C for further use.

Western blotting

Only the insoluble fraction was used to probe for APP processing machinery via western blotting. Protein concentration measurement as well as protocol for SDS-PAGE and western blotting with 10–20% gradient gels (Novex) were carried out as previously described⁹. Details of antibodies used for western blotting are listed in Supplementary Tables 7 and 8. For chemiluminescent blots, equal amounts of Western Lightning Plus ECL Oxidizing Reagent Plus and Enhanced Luminol Reagent Plus (PerkinElmer) were first mixed and then applied onto the membrane. To visualize protein with low abundance, SuperSignal West Femto Stable Peroxide and Luminol/Enhancer (Thermo Fisher Scientific) were instead used. Upon washing in TBS-T three times for 10 min each, membranes were fluorescently scanned using an Odyssey platform (LI-COR) or using a ChemoStar imager (Intas) for chemiluminescent visualization. For quantification, background was subtracted, and bands were analyzed using Fiji. Target protein content was normalized to the FastGreen bands of respective controls as indicated in the graphical representations.

Electrochemiluminescence A β immunoassay

To determine A β levels in specific brain regions, we turned to the V-PLEX Plus A β Peptide Panel 1 (6E10) kit (Meso Scale Discovery (MSD)) and conducted experiments based on instructions provided by the manufacturer. The kit allows multiplex measurement of A β 38, A β 40 and A β 42 from single wells. First, 150 μl of Diluent 35 was added into each well for blocking before the plates were sealed and incubated with shaking at room temperature for 1 h. Each well was subsequently washed three times with 150 μl of wash buffer containing 0.05% Tween 20 in PBS (PBS-T). From a detection antibody solution containing $50\times$ SULFO-TAG anti-A β 6E10 antibody diluted in Diluent 100, 25 μl was added into each well, followed by the addition of 25 μl of samples or calibrators per well. The plate was again sealed and incubated with shaking at room temperature for 2 h. Each well was again washed three times with 150 μl of PBS-T (0.05% Tween 20 in PBS) before the addition of 150 μl of $2\times$ Read Buffer T. Lastly, plate measurement was carried out using the MSD QuickPlex SQ 120 reader. In all assays performed, two technical replicates of samples and calibrators were included.

Data analysis, statistics and figure preparation

All statistical analyses and preliminary graphs were performed with GraphPad Prism 8.0.2. Statistical tests were chosen based on tests for normality. Experimenters were blinded in the analysis of electron microscopy data. Due to the visible effects that *Bace1* cKO has on the plaque load, blinding was not possible for various imaging analyses. No statistical methods were used to pre-determine sample sizes, but sample sizes for primary experiments (that is, quantitative LSM of cKOs and immunoassay) are similar to those shown in our previous publication⁹. The specific statistical analyses performed are listed in the respective figure legends. No animals or data points were excluded from this study. Brain connectivity images were adapted from the Allen Brain Atlas: Mouse Connectivity: Projection (<https://connectivity.brain-map.org/>)⁴³. All figures were prepared with Adobe Illustrator 28.3.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The four mouse scRNA-seq/snRNA-seq datasets analyzed were obtained from Depp et al. (GSE178295 and GSE208683)⁹, Ximerakis et al. (GSE129788)¹⁰ and Zeisel et al. (SRP135960)¹¹. The three human scRNA-seq/snRNA-seq datasets were obtained from Zhou et al. (accessed via the AD Knowledge Portal under study snRNAseqAD_TREM2)¹², Jäkel et al. (GSE118257)¹³ and Lake et al. (GSE97942)¹⁴. Source data are provided with this paper.

Code availability

The code used for snRNA-seq is available on GitHub at https://github.com/TSun-tech/2023_Sasmita_OL_BACE.

References

- Hao, Y. et al. Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587 (2021).
- Allen, M., Poggiali, D., Whitaker, K., Marshall, T. R. & Kievit, R. A. Raincloud plots: a multi-platform tool for robust data visualization. *Wellcome Open Res.* **4**, 63 (2019).
- Wickham, H. *ggplot2: Elegant Graphics for Data Analysis* (Springer, 2009).
- Saito, T. et al. Single App knock-in mouse models of Alzheimer's disease. *Nat. Neurosci.* **17**, 661–663 (2014).
- Hu, X., Das, B., Hou, H., He, W. & Yan, R. BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. *J. Exp. Med.* **215**, 927–940 (2018).

36. Lappe-Siefke, C. et al. Disruption of *Cnp1* uncouples oligodendroglial functions in axonal support and myelination. *Nat. Genet.* **33**, 366–374 (2003).
37. Goebbels, S. et al. Genetic targeting of principal neurons in neocortex and hippocampus of NEX-Cre mice. *Genesis* **44**, 611–621 (2006).
38. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* **13**, 133–140 (2010).
39. Oakley, H. et al. Intraneuronal β -amyloid aggregates, neurodegeneration and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J. Neurosci.* **26**, 10129–10140 (2006).
40. Weil, M. T. et al. Isolation and culture of oligodendrocytes. *Methods Mol. Biol.* **1936**, 79–95 (2019).
41. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
42. Wirths, O. Extraction of soluble and insoluble protein fractions from mouse brains and spinal cords. *Bio Protoc.* **7**, e2422 (2017).
43. Oh, S. W. et al. A mesoscale connectome of the mouse brain. *Nature* **508**, 207–214 (2014).

Acknowledgements

We would like to thank all personnel of the animal facility of the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT), City Campus; A. Fahrenholz for her technical contribution in sample preparation for imaging experiments; B. Sadowski for sample preparation for electron microscopy; members of the KAGS subgroup and the Department of Neurogenetics for scientific input; U. Muller and V. Bengelsdorff for the preparation and transport of APP KO tissue; S. Rossner for the 1D1 antibody recommendation; and M. Thalmann for his input on statistical analysis and data segmentation. Work pertaining to this manuscript was performed in the laboratory of K.-A.N. and was supported by the Deutsche Forschungsgemeinschaft (DFG, TRR274), the Dr. Myriam and Sheldon Adelson Medical Foundation (AMRF) and an ERC Advanced Grant (MyelinANO). Work carried out in the laboratory of O.W. is supported by the DFG (WI3472/11-1). We would like to extend our gratitude to the team behind the Allen Brain Atlas: Mouse Connectivity: Projection. We also extend our gratitude to the Gene Expression Omnibus and the AD Knowledge Portal data platforms. The valuable data provided by these platforms owe their existence to the dedication of research volunteers and the collaborative efforts of contributing researchers.

Author contributions

A.O.S., C.D. and K.-A.N. conceptualized and designed the experiments. A.O.S. and T.N. planned and performed imaging and biochemical experiments. T. Sun arranged and analyzed snRNA-seq datasets. X.Y., S.M. and S.B.S. executed in vitro culture experiments.

C.B. provided technical assistance, prepared samples for imaging and executed biochemical experiments. E.C.O. carried out biochemical experiments. Y.B.N. and G.S. planned and carried out cell sorting experiments for cKO validation. Z.W. and T.R. prepared samples and advised on electron microscopy experiments. B.B. assisted in developing an automated analysis pipeline for ISH quantification. B.B. and S.B.S. performed confocal imaging. L.E. and S.J. performed and analyzed ISH on human tissue. B.M. guided and assisted with the electrochemiluminescence assay. S.S. and S.M. assisted in data analysis. F.B. and K.O. performed all genotyping. L.S. and S.A.B. conducted pilot biochemical experiments. S.E. optimized in vitro culture experiments. K.R.S. and R.V. supplied constitutive BACE1 KO brains and the 3D5 antibody for imaging and biochemical experiments. S.G. provided and collected tissue from *Cnp-Cre* stop-flox tdTomato and *Nex-Cre* mice and provided valuable scientific input. T. Saito and T. Saido provided *APP^{MLGF}* mice and valuable scientific input. G.C.-B. provided infrastructure for and assisted with computation of mouse snRNA-seq datasets. W.M. provided access to equipment and materials for electron microscopy. H.-W.K. and O.W. advised on the electrochemiluminescence assay and provided valuable scientific input. J.W. provided infrastructure for the electrochemiluminescence assay. S.J. provided and advised on human ISH data and provided valuable scientific input. R.Y. provided *Bace1^{fl/m}* mice and valuable scientific input. A.O.S. analyzed data and constructed figures. A.O.S., C.D. and K.-A.N. prepared the manuscript.

Funding

Open access funding provided by Max Planck Society.

Competing interests

The authors declare no competing interests.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41593-024-01730-3>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41593-024-01730-3>.

Correspondence and requests for materials should be addressed to Andrew Octavian Sasmita, Constanze Depp or Klaus-Armin Nave.

Peer review information *Nature Neuroscience* thanks Ben Emery and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.


Reprints and permissions information is available at www.nature.com/reprints.



Extended Data Fig. 1 | See next page for caption.


Extended Data Fig. 1 | Expression levels and positive rates of amyloidogenic pathway genes across all cell types in the nervous system. (a) Expression level half violin plots of amyloidogenic pathway genes in all cell types of mouse nervous tissue inputs with SCTransform normalization method from all chosen mouse datasets^{9,26,27}. (b) Expression level half violin plots of amyloidogenic pathway genes in all cell types of human nervous tissue inputs with SCTransform normalization from all chosen human datasets^{28–30}. (a, b) Half violins represent aggregated expression levels of respective genes from each cell type and data

points refer to individual expression levels from single cells or nuclei normalized by the SCTransform method. (c) Positive rate barplots of amyloidogenic pathway genes in all cell types of mouse nervous tissue inputs from all chosen mouse datasets^{9,26,27}. (d) Positive rate barplots of amyloidogenic pathway genes in all cell types of human nervous tissue inputs with SCTransform normalization method from all analyzed human datasets^{28–30}. The results published here are based on data obtained from GEO and the AD Knowledge Portal.




Extended Data Fig. 2 | OLs exhibit protein expression of APP and an abundance of APP and BACE1 transcripts. (a) A confocal image of an *in vitro* OL with APP present in the soma and cellular processes. Experiment was repeated thrice in separate *in vitro* cultures. (b) A confocal image of *in vivo* mouse cortical OLs with APP present in the perinuclear space. Experiment was repeated thrice in separate *in vitro* cultures. (c) A fluorescence microscopy image of human cortical OLs showing APP reactivity in the perinuclear space. Immunolabeling was performed once on all control human samples ($n = 3$). (d) ISH images of human cortical layers 5–6 with visible APP puncta in MBP+ cells of control

(left) and AD (right) patients. Arrowheads point to APP-expressing OLs. (e) ISH images of human cortical layers 5–6 with visible BACE1 puncta in MBP+ cells of control (left) and AD (right) patients. Arrowheads point to BACE1-expressing OLs. (f) Quantification of nuclear count, MBP+ nuclei, MBP+ APP+ nuclei, and MBP+ BACE1+ nuclei in control ($n = 3$) and AD ($n = 3$ –4) patients. One-way ANOVA was performed with Sidak multiple comparison tests (P values indicated in graphs with significance highlighted in bold) comparing AD patients to controls. Bars represent means with SEM, and individual data points are displayed.



Extended Data Fig. 3 | Validation of *Cre* specificity in *Cnp-Cre* stop-flox tdTomato mice. (a) Fluorescence microscopy sagittal overview of a *Cnp-Cre* stop-flox tdTomato mouse. (b–d) Closeup images of cortex, hippocampus, and CC of a *Cnp-Cre* stop-flox tdTomato mouse. Yellow arrowheads point to RFP+ OLs and the blue arrowhead points to a single RFP+ neuron in the cortex.


(e) Barplots showing percentages of RFP+ OLs and neurons in specific brain regions. Mean percentage values are shown above each bar. Rounded average total number of cells considered for quantification is as follows: Cortex–OLs=283, cortex–neurons=9,232, hippocampus–OLs=66, hippocampus–neurons=3,203, CC–OLs=344, CC–neurons=1.



Extended Data Fig. 4 | See next page for caption.

Extended Data Fig. 4 | ISH validation of *Bace1* cKO in *OL-Bace1^{cko};AD* and *ExN-Bace1^{cko};AD*. (a–d) ISH validation of *Bace1* cKO in cortical ExNs. **(e–g)** ISH validation of *Bace1* cKO in fimbria OLs. **(h–m)** ISH validation of *Bace1* cKO in hippocampal ExNs. **(a)** Fluorescence microscopy images of cortices showing reductions of *Bace1* transcripts in ExNs of *ExN-Bace1^{cko};AD* samples. **(b)** Violin plots showing individual mouse distribution of *Bace1* puncta/cortical ExN nuclei. **(c)** Frequency distribution heatmap of individual mouse distribution of *Bace1* puncta/cortical ExN nuclei. **(d)** Violin plots showing cortical layer-specific individual mouse distribution of *Bace1* puncta/ExN nuclei. **(e)** Fluorescence microscopy images of hippocampal fimbriae showing reductions of *Bace1* transcripts in OLs of *OL-Bace1^{cko};AD* samples. **(f)** Violin plots showing individual mouse distribution of *Bace1* puncta/fimbria OL nuclei. **(g)** Frequency


distribution heatmap of individual mouse distribution of *Bace1* puncta/fimbria OL nuclei. **(h–j)** Fluorescence microscopy images of hippocampal CA1, CA2/3, and DG respectively showing reductions of *Bace1* transcripts only in ExNs of *ExN-Bace1^{cko};AD* samples. **(k)** Violin plots showing individual mouse distribution of *Bace1* puncta/hippocampal ExN nuclei. **(l)** Frequency distribution heatmap of individual mouse distribution of *Bace1* puncta/hippocampal ExN nuclei. **(m)** Violin plots showing hippocampal region-specific individual mouse distribution of *Bace1* puncta/ExN nuclei. For **(b,d,f,k,m)**, comparison was made between control, *OL-Bace1^{cko};AD*, and *ExN-Bace1^{cko};AD* mice ($n = 2$ per group). Solid lines represent median and faded lines represent quartiles. For **(c,g,l)**, n -numbers refer to amount of nuclei considered for each region and cell type analysis and make up the data cloud for violin plots shown in **(b,d,f,k,m)**.



Extended Data Fig. 5 | See next page for caption.

Extended Data Fig. 5 | Validation of BACE1 and APP antibodies with KO materials. **(a)** Confocal images of primary OLs harvested from *Control*;AD and *OL-Bace1^{cko}*;AD mice labeled with PLP (yellow), APP (blue), and 3D5 for BACE1 (white). The punctate 3D5 labeling is equally present in *Control*;AD and *OL-Bace1^{cko}*;AD, suggesting an unspecific BACE1 staining. Experiment was repeated twice in separate in vitro cultures. **(b)** Confocal images of primary OLs harvested from *Control*;AD and *OL-Bace1^{cko}*;AD mice labeled with PLP (yellow), APP (blue), and ab183612 for BACE1 (white). No BACE1 reactivity could be detected. Experiment was repeated twice in separate in vitro cultures. **(c)** Fluorescence microscopy images of mossy fibers of 9-month-old WT (left) and constitutive BACE1 KO (right) animals labeled with 3D5 (top) and ab183612 (bottom) for BACE1 (white). Loss of mossy fiber staining was only detected via 3D5 labeling. Immunolabeling was performed once on brain slices from different mice (n = 2 per group). **(d)** Confocal images of 9-month-old WT (top) and constitutive BACE1 KO (bottom) cortices labeled with DAPI (gray) and 3D5 for BACE1 (blue). Note the absence of any intracellular staining of 3D5 in both WT and BACE1 KO animals, hinting at the inability of the 3D5 antibody to detect BACE1 in cell somas. Immunolabeling was performed once on brain slices from different mice (n = 2 per group). **(e)** Immunoblot representative images of BACE1


and the loading control, actin, on sorted OLs from 1-month-old *Control*;AD and *OL-Bace1^{cko}*;AD (n = 1 per group), showing a proof of concept ablation of BACE1 in a cell-type-specific manner. **(f)** Fluorescence microscopy images of piriform cortices of 3-month-old WT (left) and constitutive APP KO (right) animals labeled with CA11 (yellow) and Y188 for APP (blue) for BACE1 (white). APP reactivity, including the APP labeling in OL soma (insets), is abolished in the KO tissue. Immunolabeling was performed once on brain slices from different mice (n = 2 per group). **(g-h) Cell-type-specific deletion of *Bace1* alters APP processing.** **(g)** Immunoblots and total protein content of microdissected cortical and WM tissues from 6-month-old male mice targeting key amyloidogenic proteins in lysates. **(h)** Immunoblot quantification showing APP processing in WT, control, *ExN-Bace1^{cko}*;AD and *OL-Bace1^{cko}*;AD (n = 4–6 per group) lysates. Top—cortical, bottom—WM. All immunoblots were normalized to WT relative protein amount except β -CTFs which were normalized to control AD relative protein amount. Data was statistically analyzed via one-way ANOVA was performed with Tukey multiple comparison tests (*P* values indicated in graphs with significance highlighted in bold). Bars represent means with SEM and individual data points displayed.



Extended Data Fig. 6 | See next page for caption.

Extended Data Fig. 6 | Female *APP^{NLGF}* animals develop more A β plaque burden compared to age-matched male *APP^{NLGF}* animals. (a) LSM 3D visualization of female and male control *APP^{NLGF}* hemibrains at 6 months of age. (b) Brain region-segmented plaques of female and male control *APP^{NLGF}* hemibrains. Color-region allocation is as follows: White–isocortex, blue–hippocampus, yellow–alveus. (c) Fluorescence microscopy images of female and male control *APP^{NLGF}* cortices. (d) Quantification of LSM data between female and male control *APP^{NLGF}* hemibrains (n = 10 per sex). Male data points were normalized to female data. Filled shapes represent male and hollowed shapes


represent female mice. For each parameter, unpaired, two-tailed Student's *t*-test was performed (*P* values indicated in graphs) comparing males to females. Bars represent means with s.e.m. and individual data points are displayed. Raw unnormalized data is available in Supplementary Table 1. (e,f) Quantification of A β load and microgliosis in different brain regions of male and female control *APP^{NLGF}* mice (n = 4 per sex). Unpaired, two-tailed Student's *t*-test was performed for each regional quantification (*P* values indicated in graphs with significance highlighted in bold) comparing males to females. Bars represent means with SEM and individual data points displayed.



Extended Data Fig. 7 | See next page for caption.

Extended Data Fig. 7 | Microgliosis is proportional to A β burden. (a) Coronal sections of female control, *OL-Bace1^{cko};AD* and *ExN-Bace1^{cko};AD* mouse hemibrains stained for microglia (Iba1) and A β (6E10). **(b,c)** Closeup images of cortex and WM of control and cKO mice showing moderate and marked reductions of both A β deposits and microgliosis in *OL-Bace1^{cko};AD* and *ExN-Bace1^{cko};AD* samples, respectively. Inherent changes in microgliosis could thus be excluded as microglia only appear reactive to plaques and not in regions


devoid of them. **(d,e)** Quantification of A β load and microgliosis between controls and cKOs (n = 5 per group) spanning different regions. Microgliosis was shown to be directly linked to plaque load. One-way ANOVA was performed with Tukey multiple comparison tests (*P* values indicated in graphs with significance highlighted in bold). Bars represent means with SEM and individual data points displayed.



Extended Data Fig. 8 | Thalamic plaques contain Aβ derived from cortical and hippocampal sources and plaque deposition is not directly proportional to *APP^{NLGF}* gene dosage.

(a) Fluorescence microscopy images of thalami of control and *ExN-Bace1^{CKO}*;AD samples with no apparent reduction in *Bace1* transcripts in ExNs. (b) Violin plots showing individual mouse distribution of *Bace1* puncta/thalamic nuclei. Solid lines represent medians and faded lines represent quartiles. (c) Isocortical regions containing neuronal projections into the thalamus (left) and the inferior colliculus (right). Inferior colliculus primarily receives cortical input from the auditory cortex. Images were adapted from the Allen Brain Atlas: Mouse Connectivity: Projection (<https://connectivity.brain-map.org/>). (d) Fluorescence microscopy images of 5xFAD mouse cortex (left) and thalamus (right) stained for Aβ42 (blue) and human-specific APP (yellow). White arrowheads point to neuronal somas in the cortex but not the thalamus of 5xFAD mice positive for human-specific APP. Immunolabeling was performed once on brain slices of 6-month-old 5xFAD mice (n = 4) (e-g) **Plaque deposition**


is not directly proportional to *APP^{NLGF}* gene dosage. (e) LSM 3D visualization of female WT, heterozygous, and homozygous *APP^{NLGF}* hemibrains at 6 months of age. (f) Quantification of LSM data between female homozygous (n = 10) and heterozygous *APP^{NLGF}* mice (n = 7). Heterozygous data points were normalized to homozygous data. Circles represent homozygous *APP^{NLGF}* mice and half-filled circles represent heterozygous *APP^{NLGF}* mice. For each parameter, unpaired, two-tailed Student's *t*-test was performed (*P* values indicated in graphs) comparing the two groups. Bars represent means with SEM and individual data points displayed. Raw unnormalized data is available in Supplementary Table 3. (g) Immunoblot of 6-month-old male homozygous *APP^{NLGF}*, heterozygous *APP^{NLGF}*, and WT mice labeled for APP (n = 2 per group). Heterozygous mice express half of the *APP^{NLGF}* gene dosage, resulting in a FL-APP level between WT and homozygous *APP^{NLGF}* mice. This is accompanied by a concomitant accumulation of half β-CTFs in heterozygous lysates compared to the homozygous amount.



Extended Data Fig. 9 | See next page for caption.

Extended Data Fig. 9 | Considerable plaque deposition occurs in older *ExN-Bace1^{cko};AD* mice and double *Bace1* cKO in OLs and ExNs ablated cerebral A β burden. (a) LSM 3D visualization of female *ExN-Bace1^{cko};AD* mice at 3, 6, 9, and 12 months alongside a *Control;AD* mouse brain at 6 months stained with Congo Red. Bottom right insets represent 2D cortical planes with yellow arrowheads pointing to plaques. (b) Quantification of LSM total cortical plaque volume between *ExN-Bace1^{cko};AD* at various time points ($n = 3\text{--}5$ per group). Normalization of *ExN-Bace1^{cko};AD* data points to *Control;AD* data points was performed. Blue bars represent *ExN-Bace1^{cko};AD* data points and the gray bar represents *Control;AD*. An unpaired, two-tailed Student's *t*-test was performed (*P* values indicated in the graph with significance highlighted in bold) comparing 12-month-old *ExN-Bace1^{cko};AD* and 6-month-old *Control;AD* data. Bars represent means with SEM and individual data points displayed. Raw unnormalized data is available in Supplementary Table 4. (c–f) **Double *Bace1* cKO in OLs and ExNs ablated cerebral A β burden.** Light sheet microscopy data of plaque burden (Congo red) comparing 6-month-old *OL-ExN-Bace1^{cko};AD* male mice to age- and sex-matched *ExN-Bace1^{cko};AD* mice. Color-region allocation is as follows: White–isocortex, blue–hippocampus, yellow–alveus, pastel blue–inferior colliculus, pastel yellow–thalamus. (c) LSM 3D visualization of *ExN-Bace1^{cko};AD* and *OL-ExN-Bace1^{cko};AD* male mouse hemibrains. (d) Brain region-segmented plaques of *ExN-*

Bace1^{cko};AD and *OL-ExN-Bace1^{cko};AD* male mouse hemibrains. (e) Quantification of LSM data between *ExN-Bace1^{cko};AD* ($n = 5$) and *OL-ExN-Bace1^{cko};AD* ($n = 3$) hemibrains. Normalization of *OL-ExN-Bace1^{cko};AD* data points was performed to *ExN-Bace1^{cko};AD*. Hollowed triangles represent *ExN-Bace1^{cko};AD* and hollowed squares represent *OL-ExN-Bace1^{cko};AD*. For each parameter, unpaired, two-tailed Student's *t*-test was performed (*P* values indicated in graphs) comparing the two groups. Bars represent means with SEM and individual data points displayed. Raw unnormalized data is available in Supplementary Table 5. (f) A β 42 electrochemiluminescence immunoassay data of insoluble (SDS-soluble, left) and soluble (Tris-NaCl-soluble, right) lysates of microdissected cortical (top) and WM (bottom) tissues from *ExN-Bace1^{cko};AD* ($n = 7$) and *OL-ExN-Bace1^{cko};AD* ($n = 3$) fractions of 6-month-old male mouse hemibrains. Data points were normalized to *ExN-Bace1^{cko};AD* samples. The small amount of A β 42 still produced in *ExN-Bace1^{cko};AD* fractions is almost completely ablated in *OL-ExN-Bace1^{cko};AD* fractions, highlighting the OL contribution to A β 42 even in the absence of A β 42 from ExNs. An unpaired, two-tailed Student's *t*-test was performed (*P* values indicated in the graph with significance highlighted in bold) comparing the two groups. Bars represent means with SEM and individual data points displayed. Raw unnormalized data are available in Supplementary Table 6.



Extended Data Fig. 10 | See next page for caption.

Extended Data Fig. 10 | *Bace1* cKO does not result in changes to neuronal numbers, axonal densities, and myelination profile. (a) Closeups of fluorescence microscopy images of cortices of controls and cKOs highlighting unchanged density of neurons and axons in both cKO lines at a gross level. (b) Quantification of neuronal and axonal densities between 6-month-old female controls and cKOs ($n = 5$ per group) in the isocortex. (c–g) ***Bace1* cKO does not alter myelination profile.** (c) Closeups of fluorescence microscopy images of cortices of controls and cKOs highlighting unchanged density of OLs and myelination in both cKO lines at a gross level. (d) Quantification of OL density between controls and cKOs ($n = 5$ per group) spanning different regions. (e) Quantification of myelin density between controls and cKOs ($n = 5$ per group) spanning different regions. As CC and alveus are densely

myelinated tracts, mean intensity values were instead measured.

(f) Representative electron micrographs of caudal corpus callosum (CC) of controls and cKOs at 6 months of age. (g) Analysis of myelin thickness via g-ratio measurement with single dots representing single myelinated axons quantified (*Control*; $AD = 397$, *OL-Bace1*^{cKO}; $AD = 417$, *ExN-Bace1*^{cKO}; $AD = 394$). Lines represent linear regressions of each group and shaded area indicates error bars. Myelinated axon counts and mean g-ratio comparisons from electron micrographs of controls and cKOs ($n = 4$ per group). For (b,d,e,g), one-way ANOVA was performed with Tukey multiple comparison tests (P values indicated in graphs with significance highlighted in bold). Bars represent means with SEM and individual data points displayed.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
☐	☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒ The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
☒	☐ A description of all covariates tested
☐	☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
☒	☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Imaging data were acquired using ZEN (v3.3, Zeiss), LAS X (Leica), and InspectorPro (v. 7_124, LaVision Biotech)
Data analysis	Statistical testing was performed in Prism8.0 (Graphpad) or R (version 4.04, R Core Team 2021). For image analysis: Vision 4D (Arivis, Versions: 3.2, 3.3), FIJI v1.53t (Open source), CaseViewer (3D HISTEC, Versions: 2.3.2, 2.4). For sequencing analysis: CellRanger toolkit v3.0.2 and CellRanger toolkit v6.1.2 (10x Genomics), R package Seurat v3.2.3. and Seurat v4.1.1. scRNA-seq data visualization was assisted by R package raincloudplots (version 0.0.4) and ggplot2 (version 3.4.4). The code used for single-nuclei transcriptome sequencing is available on GitHub https://github.com/TSun-tech/2023_Sasmita_OL_BACE .

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All raw sequencing data, as well as raw and processed counts matrices have been uploaded to the Gene expression Omnibus (GEO)101 under the following SuperSeries accession number: The four mouse scRNA-Seq/snRNA-Seq datasets analyzed were obtained from Depp, Sun, et al., 2023 (GSE178295, GSE208683), Ximerakis et al., 2019 (GSE129788), and Zeisel et al., 2018 (SRP135960). The three human scRNA-Seq/snRNA-Seq datasets were obtained from Zhou et al., 2020 (access via AD Knowledge Portal under study snRNAseqAD_TREM2), Jäkel et al., 2019 (GSE118257), and Lake et al., 2018 (GSE97942). Source data are provided with this paper.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

Sexes of patients whose samples are derived from are reported. Sex-specific analysis was not performed due to the small number of patient samples. Additionally, experiments involving human samples are proof-of-principle experiments to deduce the expression of amyloidogenic components in human OLs, hence, both sexes are grouped together based on whether they are AD patients or control cases.

Reporting on race, ethnicity, or other socially relevant groupings

N/A

Population characteristics

Human patient samples (Control – 1 female, 2 male, age: 74±2.83 years; AD – 2 female, 2 male, age: 72.75±1.78 years) were utilized for the in situ hybridization experiment. Selection of patients was performed upon Braak staging with AD patient scores ranging from Braak 5-6 and control patient scores ranging from Braak 1-3. Post-mortem interval of patients ranged between 26-51 h. APOE genotype of all control patients are 3/3, while AD patient APOE genotypes are: 3/3, 3/4, and 4/4.

Recruitment

All samples were obtained from the Neurobiobank Munich (Germany).

Ethics oversight

Ethical approval for the use of human post-mortem material was received from the Ethical Committee at the Ludwig-Maximilians University in Munich, Germany. The brainbank itself has ethical approval to collect post-mortem material to be used for scientific purposes. From all donors or their next of kin informed consent has been obtained.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

Precalculations of sufficient sample size was not possible as biological effect sizes of the various experimental interferences could not be predetermined. Sample size dependent on availability of mice and previous experiences in regards to histological assessments, analysis of sequencing data etc. No statistical methods were used to pre-determine sample sizes but sample size for primary experiments (i.e., quantitative light-sheet microscopy of cKOs and immunoassay) are comparable to those shown in our past publication (Depp, Sun, et al., 2023).

Data exclusions

No animal or data points were excluded from this study.

Replication

Individual mice were seen as replicates in the case of microscopic analysis, Western blotting, immunoassay, and sequencing analysis. Representative images for qualitative inferences were repeated from at least 2 separate in vitro cultures or 2 separate animals per group to successfully validate antibody specificity and knockouts.

Randomization

In our study, most experimental cohorts were defined by genotype and littermate controls were analyzed.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Methods	
n/a	Involved in the study	n/a	Involved in the study
☐	☒ Antibodies	☒	☐ ChIP-seq
☒	☐ Eukaryotic cell lines	☒	☐ Flow cytometry
☒	☐ Palaeontology and archaeology	☒	☐ MRI-based neuroimaging
☐	☒ Animals and other organisms		
☒	☐ Clinical data		
☒	☐ Dual use research of concern		
☒	☐ Plants		

Antibodies

Antibodies used	Primary antibodies used (Anti-): 6E10 (mouse, 1:1000, BioLegend, 803001), Actin (mouse, 1:1000, Sigma, A3853), APP-1D1 (rat, 1:500, Sigma, MABN2287), APP-Y188 (rabbit, 1:500, Abcam, ab32136), BACE1 (rabbit, 1:250, Abcam, ab183612), BACE1-3D5 (mouse, 1:250, Gifted by Vassar lab, culture supernatant), BCAS1 (guinea pig, 1:250, Synaptic Systems, 445 003), CAII (rabbit, 1:1000, Abcam, ab124687), Iba1 (rabbit, 1:500, Wako, 019-19741), NeuN (chicken, 1:500, Aves, NUN), PLP-aa3 (rat, 1:200, Generated in-house, culture supernatant), RFP (rabbit, 1:500, Rockland, 600-401-379), APP (rabbit, 1:500, Synaptic Systems, 127 003), PSEN1 (rat, 1:500, Sigma, MAB1563). Secondary antibodies used (Anti-): guinea pig DL 650 (Goat, 1:1000, Invitrogen, SA5-10097), mouse Alexa 555 (Donkey, 1:1000, Invitrogen, A-31570), mouse DL 488 (Goat, 1:1000, Dianova, 115-485-003), mouse HRP (Goat, 1:10000, Dianova, 115-035-003), mouse IRDye 680 (Goat, 1:5000, Licor, 926-68070), rabbit Alexa 488 (Donkey, 1:1000, Invitrogen, A-21206), rabbit Alexa 555 (Donkey, 1:1000, Invitrogen, A-31572), rabbit DL 650 (Donkey, 1:1000, Invitrogen, SA5-10041), rabbit HRP (Goat, 1:10000, Dianova, 111-035-003), rabbit IRDye 800 (Goat, 1:5000, Licor, 926-32211), rat DL 488 (Goat, 1:1000, Invitrogen, SA5-10018), rat DL 650 (Donkey, 1:5000, Invitrogen, SA5-10029). Full details on antibodies utilized in this study and their experimental usage can be found in Table S7 and Table S8.
Validation	Wherever applicable, validation of antibodies on APPNLGF or corresponding conditional Bace1 knock-outs was performed. Staining or immunoblotting performance was evaluated based on comparison to typical staining patterns that should be observed in APPNLGF animals according to published studies (e.g. staining of amyloid plaques or coralling of glial cells, upregulation in APPNLGF mice). These antibodies were utilized for validation: anti-Aβ-6E10 (mouse, BioLegend, 1:1000); anti-Iba1 (rabbit, Wako, 1:500). Validation of Bace1 conditional knock-outs were performed via in situ hybridization, Western blotting with the antibody anti-BACE1-3D5 (mouse, hybridoma culture supernatant, 1:500), and immunoassay of amyloid beta on the Meso Scale Discovery platform. Myelin protein specific antibody, anti-PLP-clone aa3 (rat, culture supernatant; 1:200), was validated in house against the corresponding knock-out animal (data not shown).

Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	This study involved mice on the C57/BL6N background. Transgenic/genetically modified animals used were: APPNLGF (Saito et al., 2014), Cnp-Cre (Lappe-Siefke et al., 2004), Nex-Cre (Goebbels et al., 2006), stopflox-tdTomato (Madisen et al., 2012), Bace1fl/fl (Hu et al., 2018), 5xFAD (Oakley et al., 2006). This study employed mice of various ages (i.e. for primary cell culture and imaging experiments) as indicated in the figures throughout the paper (p7 to 6-month-old) (Documentation: 24_KAN_0021_CNCBFL, 24_KAN_0026_NXCBFL, 24_KAN_0024_FFDE). Mice were group-housed in the animal facility of Max Planck Institute for Multidisciplinary Sciences (MPI-NAT), City Campus with ad libitum food and regular cage maintenance. All mice were kept under a 12 h dark and 12 h light cycle in an ambient temperature of 21C and 45% humidity. All animals are characterized as unburdened and only organ collection was performed.
Wild animals	This study did not involve wild animals.
Reporting on sex	Both sexes were utilized in this study as sex dimorphism in the APPNLGF mice is evident. When sex dimorphism is expected, such as

Reporting on sex

the light-sheet characterization of plaque burden conditional knockouts, experimental readout was assessed for both sexes. For other experiments, to reduce number of animals utilized, only one sex is chosen as changes persist regardless of sex. Sexes of animals utilized are listed in the figure and respective figure legends.

Field-collected samples

This study did not include field-collected samples.

Ethics oversight

All animal experiments were conducted in concordance with German animal welfare practices and local authorities (Documentation: 24_KAN_0021_CNCBFL, 24_KAN_0026_NXCBFL, 24_KAN_0024_FFDE).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Seed stocks

N/A

Novel plant genotypes

N/A

Authentication

N/A